Main Menu

Video: Access to state-of-the-art sequencing for industry partners

Dr Amanda Swain is Head of the Tumour Profiling Unit at the ICR, providing access to state-of-the-art sequencing technologies and unrivalled expertise in the molecular characterisation of tumours. Staff at the unit support researchers to accelerate progress towards precision therapies.

The team applies a range of cutting-edge techniques to genomic, transcriptomic and epigenomic analysis. They have access to the very latest next-generation genome sequencing technology – bringing opportunities for ultra-high-throughput sequencing of samples.

They collaborate with scientists working at the ICR and elsewhere to provide a high-quality tumour profiling service, enabling researchers to build an unprecedented level of understanding about which genetic alterations are important in driving cancer and its evolution.

The team can extract information from even the tiniest amounts of material, including tumour biopsies and circulating tumour DNA from patients taking part in clinical trials. It has analysed samples from cancers including breast, ovarian, prostate, gastric, bowel, renal, lung, salivary gland, glioblastoma and leukaemia, and can analyse thousands of samples per year.

Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.


New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.


Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.


Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.


Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.


The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.


Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.